Clinica e Investigacion en Arteriosclerosis最新文献

{"title":"Cardiovascular effects of household air pollution on cardiovascular diseases incidence.","authors":"Patricio Lopez-Jaramillo, Gladys Lizarazo, Raúl Torres, Fausto Posso, Jose P Lopez-Lopez, Maya Caicedo, Fernando Vargas-Mendoza","doi":"10.1016/j.arteri.2025.500770","DOIUrl":"https://doi.org/10.1016/j.arteri.2025.500770","url":null,"abstract":"<p><p>Cardiovascular diseases (CVD) are the main cause of death globally, especially in low- and middle-income countries (LMICs), where the largest number of inhabitants on the planet are concentrated. Air pollution inside and outside the home by microparticles 2 5 (PM2·5) has become an important risk factor for the presence of CVD and other chronic non-communicable diseases, particularly in LMICs. The use of solid fuels as an energy source for cooking food and heating inside the home has negative effects not only on human health but also on the health of the planet, as it contributes to deforestation and the consequent effect on climate change. In this narrative review we update how air pollution inside the home from cooking food with firewood and charcoal impacts the risk of CVD, the factors that determine the use of these polluting fuels, and the actions necessary for the massive transition toward the use of non-polluting energy, highlighting the development of university research to offer a stove that uses green hydrogen as a non-polluting energy source.</p>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":" ","pages":"500770"},"PeriodicalIF":1.9,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabesity and cardiovascular mortality in a prospective population cohort followed for more than 20 years.","authors":"Julio A Carbayo-Herencia, Marta Simarro Rueda, Luis Miguel Artigao Ródenas, Juan A Divisón Garrote, Francisca Molina Escribano, Isabel Ponce García, Antonio Palazón Bru, Pilar Torres Moreno, David Caldevilla Bernardo, Rosalina Martínez López, Vicente Francisco Gil Guillén, José R Banegas","doi":"10.1016/j.arteri.2025.500768","DOIUrl":"https://doi.org/10.1016/j.arteri.2025.500768","url":null,"abstract":"<p><strong>Introduction: </strong>Control of the main cardiovascular risk factors had succeeded in reducing cardiovascular diseases (CVD). However, the general increase in the prevalence of type 2 diabetes mellitus (DM2) and obesity has slowed this decline. Both CVRFs are strongly associated, and the term diabesity has been coined to refer to this relationship. The main objective of this study was to assess the influence of diabesity on cardiovascular mortality.</p><p><strong>Methods: </strong>Prospective cohort study involving 1246 individuals (54.3% women) followed for 20.9 years (SD=7.31) and selected by random two-stage sampling in a province in southeastern Spain. Diabesity was defined as the combination of DM2 with overweight and obesity. Survival curves (Kaplan-Meier) were calculated and two Cox regression models were used, one unadjusted and the other adjusted by the main explanatory variables in which the diabesity variable consisted of 6 categories (normal weight, overweight, obesity, normal weight+DM2, overweight+DM2 and obesity+DM2).</p><p><strong>Results: </strong>There were 95 deaths due to CV causes (7.6% of the total; 6.2% women and 9.3% men; p=0.01). After adjustment, the combination of DM2 and overweight increased the incidence of cardiovascular mortality by 133% (HR=2.33; 95% CI: 1.18-4.58; p=0.014) and the combination of DM2 and obesity by 49% (HR=1.49; 95% CI: 0.64-3.45; p=0.351), not reaching statistical significance in the latter case.</p><p><strong>Conclusions: </strong>In the general population, the results of our study show that the combination of overweight and DM2 is associated with higher CV mortality. It seems a priority to intervene intensively in the control of both overweight and DM2.</p>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":" ","pages":"500768"},"PeriodicalIF":1.9,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COPD and cardiovascular risk.","authors":"Carlos Santiago Díaz, Francisco J Medrano, N Muñoz-Rivas, Luis Castilla Guerra, M Belén Alonso Ortiz","doi":"10.1016/j.arteri.2024.500757","DOIUrl":"https://doi.org/10.1016/j.arteri.2024.500757","url":null,"abstract":"<p><p>Chronic Obstructive Pulmonary Disease (COPD) usually presents joined to other pathologies we call comorbidities. The more frequent of them are those related to cardiovascular risk, either its risk factors or its clinical manifestations. Cardiovascular risk of these patients grows up with the severity of the airflow obstruction, specially during and after an exacerbation of COPD. Patients with COPD have between 2 and 5 times more risk of ischaemic heart disease than people without COPD, even after adjusting for cofounding factors. Cardiovascular diseases are up to the second cause of mortality in these patients, close to those due to the lung disease. Although COPD is associated to several cardiovascular risk factors such as tobacco, arterial hypertension or Diabetes Mellitus, they don't explain all the excess in cardiovascular risk these patients have. Despite that excess of cardiovascular risk in COPD patients, most widely used cardiovascular risk scores don't include COPD as a risk factor itself, so global risk is understimated in these patients. In this review, we make a bibliography revision of the avaliable evidence about COPD and cardiovascular risk factors as well as the excess of cardiovascular risk COPD itself involves.</p>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":" ","pages":"500757"},"PeriodicalIF":1.9,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143257004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Habit of physical-sports practice and the healthy lifestyle among Spanish adults from 22 to 72 years of age.","authors":"Pedro Luis Rodríguez García, Juan José Pérez Soto, Eliseo García Cantó, Pedro Javier Tarraga Marcos, Pedro Juan Tárraga López","doi":"10.1016/j.arteri.2024.500756","DOIUrl":"https://doi.org/10.1016/j.arteri.2024.500756","url":null,"abstract":"<p><strong>Background: </strong>Physical-sports habits in adulthood constitute one of the predictors of physical, psychological and social health within healthy lifestyles.</p><p><strong>Methods: </strong>The Acquired Healthy Lifestyle Assessment Scale was applied to a sample of 788 subjects between the ages of 22 and 72 and the dimension that makes up physical-sports practice habits was analyzed.</p><p><strong>Results: </strong>74.4% of adults have habits of physical-sports practice that are not healthy or unhealthy, 18.8% tend towards health and only 6.9% are healthy. Pearson's 2 tests show a significant association between men and healthy habits, without observing changes associated with the age variable. The t-Student and one-factor ANOVA tests confirm the relationship between the level of health and physical-sports practice habits depending on sex and age.</p><p><strong>Conclusions: </strong>It is necessary to promote preventive programs to increase participation in the practice of physical and sports exercise in the adult population that has unhealthy or unhealthy levels of lifestyle.</p>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":" ","pages":"500756"},"PeriodicalIF":1.9,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143060625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of PCSK9 inhibitors in real life.","authors":"Antón González-Guerrero, Eugenia Navarrete-Rouco, David Benaiges, Eva Giralt-Steinhauer, Lidia Marcos, Anna Oliveras, Lluis Recasens, Juan Pedro-Botet","doi":"10.1016/j.arteri.2024.500755","DOIUrl":"https://doi.org/10.1016/j.arteri.2024.500755","url":null,"abstract":"<p><strong>Objective: </strong>To confirm the effectiveness and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in daily clinical practice.</p><p><strong>Methods: </strong>Retrospective observational study of patients from hospital registry of PCSK9 inhibitor treatment with a follow-up ≥ 6 months. The lipid-lowering effect and safety were evaluated.</p><p><strong>Results: </strong>Of the 193 patients included in the study, 168 (87%) had cardiovascular disease, and 54 (28%) had familial hypercholesterolemia; 85 (44%) were intolerant to statins/ezetimibe. No differences between alirocumab and evolocumab groups regarding the rate of LDL-C reduction ≥ 50% (82.8% vs. 83.1%), achievement of the therapeutic target (60.9% vs. 65.5%), or complete remission (60.2% vs. 58.5%) were found. An erythema at the injection site in one patient treated with alirocumab and urticaria in one patient treated with evolocumab were recorded. According to the logistic regression analysis, complete remission of LDL-C in subjects treated with PCSK9 inhibitors was positively associated with increased age (OR: 1.045; 95%CI: 1.0-1.092; P=.049) and active smoking (OR: 4.562; 95%CI: 1.434-14.515; P=.010), and negatively associated with female gender (OR: 0.403; 95%CI: 0.171-0.949; P=.038), baseline LDL-C levels (OR: 0.969; 95%CI: 0.957-0.981; P<.001)and statin/ezetimibe intolerance (OR: 0.403; 95%CI: 0.176-0.925; P=.041).</p><p><strong>Conclusion: </strong>This real-world practice study has confirmed that PCSK9 inhibitors are effective, safe and well tolerated, with lipid-lowering effects comparable to those described in randomized controlled trials, regardless of the monoclonal antibody used.</p>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":" ","pages":"500755"},"PeriodicalIF":1.9,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluación del efecto sobre la trombogenicidad de modificaciones de la superficie en stents de nitinol en un modelo in vitro","authors":"Javier Rodríguez Lega,&nbsp;Ángel González Pinto","doi":"10.1016/j.arteri.2024.10.002","DOIUrl":"10.1016/j.arteri.2024.10.002","url":null,"abstract":"","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 1","pages":"Article 100742"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142640066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Levels of sCD163 in women rheumatoid arthritis: Relationship with cardiovascular risk markers","authors":"Oscar Zaragoza-García ,&nbsp;Olivia Briceño ,&nbsp;José Rafael Villafan-Bernal ,&nbsp;Ilse Adriana Gutiérrez-Pérez ,&nbsp;Héctor Ugo Rojas-Delgado ,&nbsp;Gustavo Adolfo Alonso-Silverio ,&nbsp;Antonio Alarcón-Paredes ,&nbsp;José Eduardo Navarro-Zarza ,&nbsp;Cristina Morales-Martínez ,&nbsp;Rubén Rodríguez-García ,&nbsp;Iris Paola Guzmán-Guzmán","doi":"10.1016/j.arteri.2024.04.002","DOIUrl":"10.1016/j.arteri.2024.04.002","url":null,"abstract":"<div><h3>Aim</h3><div>The soluble scavenger receptor differentiation antigen 163 (sCD163), a monocyte/macrophage activation marker, is related to cardiovascular mortality in the general population. This study aimed to evaluate their relationship between serum levels of sCD163 with cardiovascular risk indicators in rheumatoid arthritis (RA).</div></div><div><h3>Methods</h3><div>A cross-sectional study was performed on 80 women diagnosed with RA. The cardiovascular risks were determined using the lipid profile, metabolic syndrome, and QRISK3 calculator. For the assessment of RA activity, we evaluated the DAS28 with erythrocyte sedimentation rate (DAS28-ESR). The serum levels of sCD163<span> were determined by the ELISA<span> method. Logistic regression models and receiver operating characteristics (ROC) curve were used to assess the association and predictive value of sCD163 with cardiovascular risk in RA patients.</span></span></div></div><div><h3>Results</h3><div>Levels of sCD163 were significantly higher in RA patients with high sensitivity protein C-reactive to HDL-c ratio (CHR)<!--> <!-->≥<!--> <!-->0.121 (<em>p</em> <!-->=<!--> <!-->0.003), total cholesterol/HDL-c ratio<!--> <!-->&gt;<!--> <!-->7% (<em>p</em> <!-->=<!--> <!-->0.004), LDL-c/HDL-c ratio<!--> <!-->&gt;<!--> <!-->3% (<em>p</em> <!-->=<!--> <!-->0.035), atherogenic index of plasma<!--> <!-->&gt;<!--> <!-->0.21 (<em>p</em> <!-->=<!--> <!-->0.004), cardiometabolic index (CMI)<!--> <!-->≥<!--> <!-->1.70 (<em>p</em> <!-->=<!--> <!-->0.005), and high DAS28-ESR (<em>p</em> <!-->=<!--> <!-->0.004). In multivariate analysis, levels of sCD163<!--> <!-->≥<!--> <!-->1107.3<!--> <!-->ng/mL were associated with CHR<!--> <!-->≥<!--> <!-->0.121 (OR<!--> <!-->=<!--> <!-->3.43, <em>p</em> <!-->=<!--> <!-->0.020), CMI<!--> <!-->≥<!--> <!-->1.70 (OR<!--> <!-->=<!--> <!-->4.25, <em>p</em> <!-->=<!--> <!-->0.005), total cholesterol/HDL-c ratio<!--> <!-->&gt;<!--> <!-->7% (OR<!--> <!-->=<!--> <!-->6.63, <em>p</em> <!-->=<!--> <!-->0.044), as well as with DAS28-ESR<!--> <!-->&gt;<!--> <!-->3.2 (OR<!--> <!-->=<!--> <!-->8.10, <em>p</em> <!-->=<!--> <!-->0.008). Moreover, levels of sCD163 predicted CHR<!--> <!-->≥<!--> <!-->0.121 (AUC<!--> <!-->=<!--> <!-->0.701), cholesterol total/HDL ratio<!--> <!-->&gt;<!--> <!-->7% (AUC<!--> <!-->=<!--> <!-->0.764), and DAS28-ESR<!--> <!-->&gt;<!--> <!-->3.2 (AUC<!--> <!-->=<!--> <!-->0.720).</div></div><div><h3>Conclusion</h3><div>Serum levels of sCD163 could be considered a surrogate of cardiovascular risk and clinical activity in RA.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 1","pages":"Article 100721"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140904932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study","authors":"Vicente Pallarés-Carratalá ,&nbsp;Antonio Ruiz-García ,&nbsp;Adalberto Serrano-Cumplido ,&nbsp;Antonio Segura Fragoso ,&nbsp;Verónica Fernández-Pascual ,&nbsp;Beatriz Sánchez-Sánchez ,&nbsp;María Inmaculada Cervera-Pérez ,&nbsp;Francisco Javier Alonso-Moreno ,&nbsp;Ezequiel Arranz-Martínez ,&nbsp;Alfonso Barquilla-García ,&nbsp;Daniel Rey-Aldana ,&nbsp;José Polo García ,&nbsp;Sergio Cinza-Sanjurjo ,&nbsp;on behalf of the Investigators of the AGORA study, of the Spanish Society of Primary Care Physicians SEMERGEN Foundation","doi":"10.1016/j.arteri.2024.05.001","DOIUrl":"10.1016/j.arteri.2024.05.001","url":null,"abstract":"<div><h3>Introduction</h3><div>Type 2 diabetes mellitus (T2D) has acquired epidemic proportions worldwide. In recent years, new oral glucose-lowering drugs (OGLD) have emerged that improve the cardiovascular–kidney–metabolic control in T2D people.</div></div><div><h3>Objectives</h3><div>To compare the baseline clinical–biological characteristics among T2D people to whom had added-on dapagliflozin (DAPA group) or another OGLD (SOC group) second-line hypoglycaemic therapies among the AGORA study population.</div></div><div><h3>Methods</h3><div>This is a multicentre cross-sectional observational study of the baseline characteristics of T2D people recruited through competitive sampling among 46 primary care health centres in Spain for the AGORA study. The inclusion and exclusion criteria of participants, and justification of the sample size are reported. After verifying the data necessary to be evaluated and informed consent, 317 subjects were included to the DAPA group and 288 to the SOC group. Both categorical and continuous variables were analysed and compared with the usual statistics. Cohen's <em>d</em> was used to assess the standardised difference in means.</div></div><div><h3>Results</h3><div>Six hundred and five patients with T2D were assessed (mean age 63.5 [SD<!--> <!-->±<!--> <!-->8.1] years, 61.8% men), whom 17.4% were smokers, 47.6% had obesity, 74.8% hypertension, 87.3% dyslipidaemia, and 41.7% reported physical inactivity, with no significant differences between both comparison groups. The mean (SD) evolution time of T2D was 10.1 (5.6) years. Most baseline clinical–biological characteristics at recruitment were similar in both groups. However, DAPA group was younger (2.9 years), and had lower systolic blood pressure (SBP) (2.8<!--> <!-->mmHg), higher body weight (BW) (3.7<!--> <!-->kg), and higher glycated haemoglobin A_1c (HbA_1c) (0.3%) than SOC group. Only 11.5% of participants had poor glycaemic control (HbA_1c <!-->&gt;<!--> <!-->8%) at recruitment, 54.9% had good glycaemic control (HbA_1c <!-->&lt;<!--> <!-->7%), being significantly lower in the DAPA group (47.3%) than in the SOC group (63.4%). The percentage of T2D patients with high vascular risk (VR) was 46.3%, and 53.7% with very high VR, being significantly higher in the DAPA group (57.4%) than in the SOC group (49.6%).</div></div><div><h3>Conclusions</h3><div>Most baseline cardiovascular–kidney–metabolic characteristics were similar in T2D patients whom had added dapagliflozin on second-line hypoglycaemic therapy as those whom had added-on another OGLD. However, patients whom had added-on dapagliflozin had higher VR, lower SBP, higher BW, and slightly worse HbA_1c control. Future research is necessary to explain the causes of these differences in cardiometabolic control.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 1","pages":"Article 100724"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141443496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Las recomendaciones nutricionales: una fácil y difícil tarea para el médico","authors":"Francisco Pérez-Jiménez","doi":"10.1016/j.arteri.2025.500764","DOIUrl":"10.1016/j.arteri.2025.500764","url":null,"abstract":"","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 1","pages":"Article 500764"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When “old” lipid lowering therapies not should be discontinued","authors":"Francesco Sbrana,&nbsp;Beatrice Dal Pino","doi":"10.1016/j.arteri.2024.08.002","DOIUrl":"10.1016/j.arteri.2024.08.002","url":null,"abstract":"","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 1","pages":"Article 100732"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142298096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}